Page last updated: 2024-09-04

irofulven and sesquiterpenes

irofulven has been researched along with sesquiterpenes in 89 studies

Compound Research Comparison

Studies (irofulven)	Trials (irofulven)	Recent Studies (post-2010) (irofulven)	Studies (sesquiterpenes)	Trials (sesquiterpenes)	Recent Studies (post-2010) (sesquiterpenes)
99	22	7	17,489	536	7,668

Research

Studies (89)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	13 (14.61)	18.2507
2000's	68 (76.40)	29.6817
2010's	5 (5.62)	24.3611
2020's	3 (3.37)	2.80

Authors

Authors	Studies
Estes, LA; Kelner, MJ; McMorris, TC; Taetle, R; Wang, W; Yu, J	1
Estes, L; Kelner, MJ; McMorris, TC; Samson, KM; Taetle, R; Wang, W	1
Chen, SF; Dexter, DL; Kelner, MJ; MacDonald, JR; Mangold, GL; McMorris, TC; Muscoplat, CC; Von Hoff, DD	1
Chapman, W; Chen, SF; Koester, SK; MacDonald, JR; Napier, C; Troyer, D; Woynarowski, JM	1
Von Hoff, DD	1
Bagnell, RD; Estes, L; Kelner, MJ; McMorris, TC; Samson, KM; Taetle, R	1
Britten, CD; Eckhardt, SG; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S	1
Blatner, G; Cannon, DJ; Cheson, BD; Murgo, A	1
McMorris, TC	1
Arnett, B; Herzig, MC; MacDonald, JR; Woynarowski, JM	1
Bagnell, RD; Estes, L; Kelner, MJ; McMorris, TC; Montoya, MA; Rutherford, M; Samson, KM; Taetle, R; Uglik, SF	1
Elayadi, AN; Hu, Y; Kelner, MJ; McMorris, TC; Yu, J	1
Cerna, C; Eckhardt, SG; Gomez, L; Hidalgo, M; Izbicka, E; MacDonald, JR; Rowinsky, EK; Von Hoff, DD; Weitman, SD	1
Estes, L; Kelner, MJ; MacDonald, JR; McMorris, TC; Samson, KM; Trani, NA	1
Herzig, MC; Higdon, AL; MacDonald, JR; Roberts, K; Woynarowska, BA; Woynarowski, JM	1
Arthaud, LE; MacDonald, JR; Marshall, RF	1
Estes, LA; Kelner, MJ; Lanham, KA; Lynn, JR; McMorris, TC; Oval, MY; Rojas, RJ; Samson, KM	1
Kelner, MJ; McMorris, TC; Ngo, HT; Wang, H; Yu, J	1
Herman, TS; MacDonald, JR; Roberts, K; Woynarowska, BA; Woynarowski, JM	1
Eckhardt, SG; Hammond, LA; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S	1
Baker, SD; Britten, CD; Clark, GM; Drengler, R; Eckhardt, SG; Felton, S; Hammond, LA; Hidalgo, M; Kuhn, JG; MacDonald, JR; Moczygemba, J; Rowinsky, EK; Siu, L; Smith, C; Smith, SL; Villalona-Calero, MA; Von Hoff, DD; Weitman, S	1
Cortes, J; Estey, E; Garcia-Manero, G; Giles, F; Kantarjian, H; Kornblau, S; Kwari, M; Murgo, A	1
DeVore, RF; Dowell, JE; Johnson, DH; Krozely, P; McCullough, N; Rogers, JS; Shyr, Y	1
Kashimoto, S; MacDonald, JR; Nakano, K; Sato, Y	1
Dawe, R; Estes, LA; Kelner, MJ; Lira, R; MacDonald, JR; McMorris, TC; Waters, SJ; Yu, J	1
Bushong, P; Muñoz, RM; Waters, SJ; Woynarowska BAHigdon, AL	1
Berg, WJ; Mazumdar, M; Motzer, RJ; Schwartz, L; Yu, R	1
Bigner, DD; Friedman, HS; Houghton, PJ; Keir, ST; Lawless, AA; Waters, SJ	1
Alberti, D; Arzoomanian, R; Bailey, H; Binger, K; Feierabend, C; MacDonald, J; Marnocha, R; Smith, C; Smith, S; Steele, T; Thomas, JP; Tutsch, KD; Wilding, G	1
Herzig, MC; Johnson, AE; Liang, H; Woynarowska, B; Woynarowski, JM	1
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA	1
Woynarowska, BA; Woynarowski, JM	1
Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P; Trani, NA; Velasco, TR	1
Eckhardt, SG; Gibbs, P; Gonzalez, R; Pierson, AS; Richards, J; Russ, P	1
Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH	1
Baekelandt, M	1
Amato, RJ; Pagliaro, L; Perez, C	1
Hoeijmakers, JH; Jaspers, NG; Kelner, MJ; McMorris, TC; Ng, JM; Raams, A; Takeda, S; Yamashita, YM	1
Herzig, MC; Liang, H; MacDonald, JR; Salinas, R; Trevino, AV; Waters, SJ; Woynarowska, BA; Woynarowski, JM	1
Kelner, MJ; McMorris, TC; Moon, SS	1
Bailly, C; Lansiaux, A	1
Abbruzzese, J; Cohen, SC; George, CS; Hoff, PM; Nasta, SD; Neubauer, M; Pazdur, RM; Winn, R	1
Alexandre, J; Brain, E; Cvitkovic, E; Lokiec, F; Raymond, E; Shah, A; Smith, S; Urien, S	1
Comisso, M; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ	1
Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ	1
Kulke, MH	1
Kelner, MJ; McMorris, TC; Staake, MD	1
Dick, RA; Kensler, TW; Yu, X	1
MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S	1
Blessing, JA; Pearl, ML; Rose, PG; Schilder, RJ	1
Alexandre, J; Brain, EC; Cvitkovic, E; Faivre, S; Goldwasser, F; Kaci, MO; Kahatt, C; Lokiec, F; MacDonald, JR; Misset, JL; Raymond, E; Smith, SL; Yovine, A	1
Burks, J; Cunningham, C; Mikell, C; Reed, E; Van Laar, ES; Wang, J; Wang, W; Wang, Y; Waters, SJ; Wiltshire, T	1
Green, MR; Herndon, JE; Sherman, CA; Watson, DM	1
Koeppel, F; Larsen, AK; Lazar, V; Poindessous, V; Raymond, E; Sarasin, A	1
Herman, TS; Macdonald, JR; Salinas, R; Trevino, AV; Waters, SJ; Woynarowska, BA; Woynarowski, JM	1
Billups, C; Bjornsti, MA; Houghton, PJ; Liang, H; Peterson, JK; Woo, MH	1
Herman, TS; Kosakowska-Cholody, T; Leal, BZ; Liang, H; Michejda, CJ; Salinas, RA; Waters, SJ; Woynarowska, BA; Woynarowski, JM	1
Alexandre, J; Cullen, M; Cvitkovic, E; Elman, M; Kahatt, C; Lee, MS; Lokiec, F; MacDonald, JR; Misset, JL; Raymond, E; Rigolet, MH; Sutherland, W; Tombal, B	1
Fitzsimmons, TD; Hammond, LA; Harrison, JM; Melendez, RF; Rowinsky, EK	1
Dent, P; Grant, S	1
Gupta, N; Lee, MS; Loewenstein, J; Milam, AH; Penson, RT; Seiden, MV; Wepner, MS	1
Arsenau, J; Berman, B; MacDonald, JR; Richards, D; Senzer, N; Smith, S	1
Calvo, F; Cvitkovic, E; Koeppel, F; Laar, ES; Larsen, AK; Lokiec, F; Poindessous, V; Raymond, E; Serova, M; Waters, SJ	1
Alberts, DS; Bodurka, DC; Cullen, M; Gordon, AN; Matulonis, UA; McGuire, WP; Penson, RT; Reed, E; Seiden, MV; Weems, G	1
Lokiec, F; Rezaí, K; Urien, S	1
Bernstein, M; Blaney, SM; Bomgaars, LR; Dale Weitman, S; Hershon, L; Kuhn, JG; Langevin, AM; Megason, GC; Pullen, J	1
Alexandre, J; Chieze, S; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Misset, JL; Raymond, E; Taamma, A; Weems, G	1
Beale, P; Boyer, M; Chan, AT; Chung, HC; Clarke, S; Goh, BC; Ho, R; Jeung, HC; Lam, KC; Lim, R; Ma, B; Mo, FK; Ng, EK; Ong, SY; Rha, SY; Roh, JK; Soo, R; Yeo, W; Zee, B	1
Liang, H	1
Cvitkovic, E; De Valeriola, D; Deroussent, A; Kahatt, C; Lokiec, F; Paci, A; Re, M; Rezai, K; Shah, A; Vassal, G; Waters, S; Weems, G; Weill, S	1
Reed, E; Senft, J; Wang, W; Wang, Y; Wiltshire, T	1
Reed, E; Senft, J; Wang, W; Wang, Y; Wenger, SL; Wiltshire, T	1
Konat, GW; Reed, E; Senft, J; Wang, W; Wang, Y; Wenger, SL; Wiltshire, T	1
Alexandre, J; Bertheault-Cvitkovic, F; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Raymond, E; Shah, A; Shibata, S; Weems, G	1
Chimmani, R; Gurram, M; Kelner, MJ; McMorris, TC; Staake, MD	1
Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P	2
Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R	1
Dings, RP; Griffin, RJ; MacDonald, JR; Mayo, KH; Van Laar, ES; Waters, SJ; Webber, J; Zhang, Y	1
Cook, PR; Escargueil, AE; Larsen, AK; Poindessous, V; Sarasin, A; Soares, DG	1
Movassaghi, M; Piersanti, G; Piizzi, G; Siegel, DS	1
Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP	1
Cervoni-Curet, FN; Erzinger, MM; Niederhuber, J; Pietsch, KE; Sturla, SJ; Whang, J; Yu, X	1
Glatt, H; Meinl, W; Pietsch, KE; Sturla, SJ	1
Dokal, I; Hossain, U; Jackson, N; Kirwan, M; Plagnol, V; Pondarre, C; Tummala, H; Vulliamy, T; Walne, AJ	1
Estes, LA; Kashinatham, A; Kelner, MJ; McMorris, TC; Staake, MD	1
Bekele, R; Börcsök, J; Brunak, S; Csabai, I; Dillon, KM; Diossy, M; Frazier, ZJ; Gao, SP; Hoffman-Censits, JH; Iyer, G; Konieczkowski, DJ; Lazaro, JB; Liu, D; Lozsa, R; Mouw, KW; Pappot, H; Plimack, ER; Rodrigues, JA; Rosenberg, JE; Rusz, O; Samant, AS; Solit, DB; Spisák, S; Szallasi, Z; Sztupinszki, Z; Szüts, D; Taplin, ME; Tisza, V; Van Allen, EM; Vasani, N	1
Greenberg, RA; Jiang, H	1
Börcsök, J; Csabai, I; Diossy, M; Duan, H; Hanlon, T; Klus, GT; Mouw, KW; Offit, K; Pappot, H; Pathania, S; Prosz, A; Ried, T; Sahgal, P; Sethi, N; Spisak, S; Stormoen, DR; Szallasi, Z; Sztupinszki, Z; Tisza, V; Topka, S; Vijai, J; Vizkeleti, L	1

Reviews

5 review(s) available for irofulven and sesquiterpenes

Article	Year
Promising new agents for treatment of patients with colorectal cancer. Seminars in oncology, 1998, Volume: 25, Issue:5 Suppl 11 Topics: Adenoviridae; Antineoplastic Agents; Benzofurans; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Duocarmycins; Enzyme Inhibitors; Humans; Indoles; Phenylurea Compounds; Sesquiterpenes; Thymidylate Synthase; Tumor Cells, Cultured; Urea	1998
Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug. Bioorganic & medicinal chemistry, 1999, Volume: 7, Issue:5 Topics: Animals; Antibiotics, Antineoplastic; Clinical Trials as Topic; Humans; Male; Mice; Models, Chemical; Prostatic Neoplasms; Rats; Sesquiterpenes; Technology, Pharmaceutical; Tumor Cells, Cultured	1999
Preferential targeting of apoptosis in tumor versus normal cells. Biochimica et biophysica acta, 2002, Jul-18, Volume: 1587, Issue:2-3 Topics: Antineoplastic Agents; Apoptosis; DNA Damage; DNA, Neoplasm; Humans; Models, Biological; Neoplasm Proteins; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Oxidation-Reduction; Sesquiterpenes; Tumor Cells, Cultured	2002
Irofulven (MGI Pharma). Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:10 Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Humans; Neoplasms; Sesquiterpenes; Structure-Activity Relationship	2002
Advanced pancreatic cancer: is there a role for combination therapy? Expert review of anticancer therapy, 2003, Volume: 3, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine Endopeptidases; Deoxycytidine; Fluorouracil; Gemcitabine; Genes, ras; Glutamates; Guanine; Humans; Multienzyme Complexes; Pancreatic Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Sesquiterpenes	2003

Trials

22 trial(s) available for irofulven and sesquiterpenes

Article	Year
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Investigational new drugs, 2001, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Camptothecin; Drug Administration Schedule; Hematologic Tests; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sesquiterpenes; Survival Rate	2001
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. Investigational new drugs, 2001, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Sesquiterpenes; Thrombocytopenia; Toxicity Tests; Treatment Outcome; Vomiting	2001
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Investigational new drugs, 2001, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Sesquiterpenes; Treatment Outcome	2001
Phase I clinical and pharmacokinetic trial of irofulven. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:6 Topics: Acidosis; Aged; Anorexia; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Sesquiterpenes; Vomiting	2001
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Investigational new drugs, 2002, Volume: 20, Issue:3 Topics: Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Sesquiterpenes	2002
Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer. Investigational new drugs, 2002, Volume: 20, Issue:4 Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Sesquiterpenes	2002
Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. American journal of clinical oncology, 2003, Volume: 26, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Sesquiterpenes; Survival Analysis	2003
Phase I population pharmacokinetics of irofulven. Anti-cancer drugs, 2003, Volume: 14, Issue:5 Topics: Adult; Aged; Algorithms; Analysis of Variance; Antineoplastic Agents; Bias; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Models, Biological; Population; Sampling Studies; Sesquiterpenes; Spectrophotometry, Ultraviolet	2003
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Sesquiterpenes; Treatment Outcome; Vomiting	2004
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Sesquiterpenes; Time Factors	2004
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 45, Issue:3 Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Sesquiterpenes; Treatment Outcome	2004
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Electroretinography; Female; Humans; Male; Middle Aged; Prognosis; Sesquiterpenes; Time Factors; Vision, Ocular	2004
Cone damage in patients receiving high-dose irofulven treatment. Archives of ophthalmology (Chicago, Ill. : 1960), 2005, Volume: 123, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Electroretinography; Female; Fluorescent Antibody Technique, Indirect; Glial Fibrillary Acidic Protein; Humans; Middle Aged; Neoplasms; Retinal Cone Photoreceptor Cells; Retinal Diseases; Rhodopsin; Sesquiterpenes; Visual Field Tests; Visual Fields	2005
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. American journal of clinical oncology, 2005, Volume: 28, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Survival Analysis	2005
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecologic oncology, 2006, Volume: 101, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Sesquiterpenes	2006
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. Journal of pharmacokinetics and pharmacodynamics, 2005, Volume: 32, Issue:5-6 Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes	2005
Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatric blood & cancer, 2006, Volume: 47, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Sesquiterpenes	2006
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Investigational new drugs, 2006, Volume: 24, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Sesquiterpenes	2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Infusions, Intravenous; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Sesquiterpenes; Stomach Neoplasms; Survival Rate; Treatment Outcome	2007
Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:11 Topics: Antineoplastic Agents, Alkylating; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Feces; Female; Humans; Infusions, Intravenous; Male; Molecular Structure; Neoplasms; Sesquiterpenes; Spectrometry, Mass, Electrospray Ionization; Tissue Distribution	2006
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Investigational new drugs, 2007, Volume: 25, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Sesquiterpenes; Treatment Outcome	2007
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome	2010

Other Studies

62 other study(ies) available for irofulven and sesquiterpenes

Article	Year
(Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. Journal of natural products, 1996, Volume: 59, Issue:9 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Basidiomycota; Chromatography, Thin Layer; Crystallography, X-Ray; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Polycyclic Sesquiterpenes; Sesquiterpenes	1996
Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Investigational new drugs, 1996, Volume: 14, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous	1996
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer research, 1997, Jan-15, Volume: 57, Issue:2 Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; HT29 Cells; Humans; Leukemia P388; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Nude; Sesquiterpenes; Transplantation, Heterologous	1997
Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochemical pharmacology, 1997, Dec-01, Volume: 54, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA; DNA Damage; DNA Fragmentation; Flow Cytometry; Humans; Sesquiterpenes	1997
Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mitomycin; Neoplasm Transplantation; Paclitaxel; Sesquiterpenes; Transplantation, Heterologous; Tumor Cells, Cultured	1998
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer research, 1999, Mar-01, Volume: 59, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous	1999
Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:2 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Sesquiterpenes	1999
Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochemical pharmacology, 1999, Jul-15, Volume: 58, Issue:2 Topics: Antineoplastic Agents; Carbon Radioisotopes; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Macromolecular Substances; Serum Albumin, Bovine; Sesquiterpenes; Thymus Gland; Tumor Cells, Cultured	1999
Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines. Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:3 Topics: Antineoplastic Agents; DNA, Neoplasm; Humans; Sesquiterpenes; Tumor Cells, Cultured	1999
Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol. Drug metabolism and disposition: the biological fate of chemicals, 1999, Volume: 27, Issue:9 Topics: Animals; Antineoplastic Agents; Biotransformation; Coloring Agents; Cytosol; DNA; Humans; In Vitro Techniques; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Protein Binding; Rats; Sesquiterpenes; Trypan Blue; Tumor Cells, Cultured	1999
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anti-cancer drugs, 1999, Volume: 10, Issue:9 Topics: Adolescent; Adult; Antineoplastic Agents; Cell Division; Child; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Sesquiterpenes; Time Factors; Tumor Cells, Cultured	1999
Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia, 2000, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Agents; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Sesquiterpenes; Topotecan	2000
Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochemical pharmacology, 2000, May-15, Volume: 59, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Carbon Radioisotopes; Cell Division; Cells, Cultured; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Sesquiterpenes; Tumor Cells, Cultured	2000
Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:5 Topics: Administration, Cutaneous; Animals; Antidotes; Antineoplastic Agents; Cold Temperature; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Male; Rats; Rats, Inbred F344; Sesquiterpenes; Skin; Thiosulfates	2000
Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anti-cancer drugs, 2000, Volume: 11, Issue:3 Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Genes, MDR; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Sesquiterpenes; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine	2000
Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene. Journal of medicinal chemistry, 2000, Sep-21, Volume: 43, Issue:19 Topics: Amino Acids; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Inhibitory Concentration 50; Peptides; Rats; Sesquiterpenes; Tumor Cells, Cultured	2000
Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiation research, 2000, Volume: 154, Issue:4 Topics: Adenocarcinoma; Androgens; Antineoplastic Agents, Alkylating; Apoptosis; Combined Modality Therapy; DNA Damage; Gamma Rays; Humans; Intestinal Mucosa; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Sesquiterpenes; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:18 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Sesquiterpenes; Topotecan; Transplantation, Heterologous	2000
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nausea; Neoplasms; Sesquiterpenes; Vomiting	2000
In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:11 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Humans; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Sesquiterpenes; Stomach Neoplasms; Xenograft Model Antitumor Assays	2001
Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues. The Journal of organic chemistry, 2001, Sep-07, Volume: 66, Issue:18 Topics: Animals; Antineoplastic Agents, Alkylating; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Mice; Sesquiterpenes; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven. Investigational new drugs, 2001, Volume: 19, Issue:4 Topics: Antineoplastic Agents, Alkylating; Cell Division; DNA Primers; Gene Expression Regulation, Neoplastic; Humans; Immunoradiometric Assay; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sesquiterpenes; Tumor Cells, Cultured	2001
Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:5 Topics: Animals; Antineoplastic Agents, Alkylating; Female; Glioblastoma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Sesquiterpenes; Transplantation, Heterologous	2001
Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status. Breast cancer research and treatment, 2002, Volume: 71, Issue:2 Topics: Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Caspase 3; Caspases; Cell Survival; DNA Fragmentation; Enzyme Activation; Female; Humans; Kinetics; Sesquiterpenes; Tumor Cells, Cultured	2002
Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:5 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Aziridines; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mitomycin; Neoplasm Transplantation; Sesquiterpenes; Thiotepa; Transplantation, Heterologous; Tumor Cells, Cultured	2002
Enhanced antitumor activity of irofulven in combination with antimitotic agents. Investigational new drugs, 2002, Volume: 20, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bridged-Ring Compounds; Cell Survival; Colchicine; Cysteine; Drug Synergism; Female; Lactones; Macrolides; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Sesquiterpenes; Taxoids; Tubulin; Tumor Cells, Cultured; Vinca Alkaloids	2002
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:9 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Dacarbazine; Dactinomycin; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Mice, SCID; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Radiation Chimera; Random Allocation; Rhabdoid Tumor; Rhabdomyosarcoma, Embryonal; Sesquiterpenes; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays	2002
Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA repair, 2002, Dec-05, Volume: 1, Issue:12 Topics: Animals; Antineoplastic Agents; Cell Line; CHO Cells; Cricetinae; DNA; DNA Damage; DNA Ligases; DNA Repair; DNA Replication; Humans; Mice; Mutation; Polycyclic Sesquiterpenes; Sesquiterpenes; Transcription, Genetic	2002
Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochemical pharmacology, 2003, Feb-15, Volume: 65, Issue:4 Topics: Antineoplastic Agents; Apoptosis; DNA Fragmentation; Gene Expression Regulation; HeLa Cells; Humans; Proto-Oncogene Proteins c-bcl-2; Sesquiterpenes	2003
Reaction of irofulven with zinc and acid. Journal of natural products, 2003, Volume: 66, Issue:2 Topics: Acetic Acid; Antineoplastic Agents, Alkylating; Chromatography, Thin Layer; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Indenes; Indicators and Reagents; Inhibitory Concentration 50; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Sesquiterpenes; Zinc	2003
[Perspectives on the oncologist pharmacopoeia]. Bulletin du cancer, 2003, Volume: 90, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin	2003
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma; Cell Line, Tumor; Cisplatin; Culture Media; Dioxoles; Drug Resistance, Neoplasm; Epithelial Cells; Glutamate-Cysteine Ligase; Glutathione Transferase; Humans; Isoquinolines; Models, Chemical; Plant Extracts; Polycyclic Sesquiterpenes; rho GTP-Binding Proteins; Sesquiterpenes; Tetrahydroisoquinolines; Time Factors; Trabectedin; Tumor Suppressor Protein p53	2003
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. International journal of oncology, 2003, Volume: 23, Issue:5 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Models, Chemical; Ovarian Neoplasms; Sesquiterpenes; Tetrazolium Salts; Thiazoles	2003
Synthesis and biological activity of enantiomers of antitumor irofulven. The Journal of organic chemistry, 2004, Feb-06, Volume: 69, Issue:3 Topics: Acylation; Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Mice; Molecular Structure; Sesquiterpenes; Stereoisomerism; Structure-Activity Relationship	2004
NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-15, Volume: 10, Issue:4 Topics: Alcohol Oxidoreductases; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Glutathione; Humans; Ketones; Kinetics; Mass Spectrometry; Models, Chemical; Polycyclic Sesquiterpenes; Sensitivity and Specificity; Sesquiterpenes; Time Factors; Transfection	2004
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. The Prostate, 2004, Apr-01, Volume: 59, Issue:1 Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Xenograft Model Antitumor Assays	2004
ATM-dependent CHK2 activation induced by anticancer agent, irofulven. The Journal of biological chemistry, 2004, Sep-17, Volume: 279, Issue:38 Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Female; Humans; Nuclear Proteins; Ovarian Neoplasms; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Serine; Sesquiterpenes; Signal Transduction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2004
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-15, Volume: 10, Issue:16 Topics: Antineoplastic Agents, Alkylating; Base Sequence; Cell Division; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cockayne Syndrome; DNA Primers; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Humans; Nuclear Proteins; Sesquiterpenes; Transcription Factors; Transcription, Genetic; Xeroderma Pigmentosum	2004
Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells. Cancer biology & therapy, 2004, Volume: 3, Issue:11 Topics: Antineoplastic Agents, Alkylating; Apoptosis; DNA Replication; G1 Phase; Gene Expression Regulation; HeLa Cells; Humans; Mitosis; Neoplasms; Proto-Oncogene Proteins c-bcl-2; S Phase; Sesquiterpenes	2004
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Irinotecan; Mice; Mice, Inbred ICR; Sesquiterpenes; Treatment Failure; Xenograft Model Antitumor Assays	2005
Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. Molecular cancer therapeutics, 2004, Volume: 3, Issue:11 Topics: Apoptosis; bcl-2-Associated X Protein; Bridged Bicyclo Compounds; Caspases; Cell Line, Tumor; Cell Proliferation; Cytochromes c; DNA Fragmentation; Enzyme Inhibitors; Humans; Male; Mitochondria; Molecular Structure; Prostatic Neoplasms; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Sesquiterpenes; Signal Transduction	2004
Acute retinal toxicity from the novel anti-tumor agent, Irofulven. Documenta ophthalmologica. Advances in ophthalmology, 2004, Volume: 108, Issue:3 Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Electroretinography; Evoked Potentials, Visual; Female; Humans; Middle Aged; Retina; Retinal Diseases; Sesquiterpenes; Visual Fields	2004
Irofulven: resurgence for alkylating therapy in cancer? Cancer biology & therapy, 2004, Volume: 3, Issue:11 Topics: Antineoplastic Agents, Alkylating; Apoptosis; G1 Phase; Gene Expression Regulation; Humans; Mitosis; Neoplasms; Proto-Oncogene Proteins c-bcl-2; S Phase; Sesquiterpenes	2004
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:4 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, p53; HT29 Cells; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Sesquiterpenes; Tetrazolium Salts; Thiazoles	2006
Comparison of antitumor activities in tumor xenograft treatment. Contemporary clinical trials, 2007, Volume: 28, Issue:2 Topics: Algorithms; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease Models, Animal; Humans; Irinotecan; Mice; Sesquiterpenes; Transplantation, Heterologous; Treatment Outcome	2007
Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochemical pharmacology, 2007, Feb-15, Volume: 73, Issue:4 Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Chromosome Aberrations; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; G1 Phase; G2 Phase; HCT116 Cells; Histones; Humans; Phosphorylation; Protein Serine-Threonine Kinases; S Phase; Sesquiterpenes; Tumor Suppressor Protein p53	2007
Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Molecular cancer therapeutics, 2006, Volume: 5, Issue:12 Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromosomes, Human; DNA Damage; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Female; Genes, BRCA1; Genes, BRCA2; Humans; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Sesquiterpenes; Transfection; Ubiquitins	2006
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Molecular pharmacology, 2007, Volume: 71, Issue:4 Topics: Antineoplastic Agents; BRCA1 Protein; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Chromosome Breakage; DNA Damage; DNA Repair; Drug Resistance; Genomic Instability; Humans; Rad51 Recombinase; Sesquiterpenes	2007
Synthesis and antitumor activity of amine analogs of irofulven. Bioorganic & medicinal chemistry letters, 2007, Dec-15, Volume: 17, Issue:24 Topics: Adenocarcinoma; Amines; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Humans; Inhibitory Concentration 50; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship	2007
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Investigational new drugs, 2008, Volume: 26, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Random Allocation; Sesquiterpenes; Xenograft Model Antitumor Assays	2008
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1 Topics: Altretamine; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; DNA Damage; DNA, Neoplasm; Drug Synergism; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Random Allocation; Sesquiterpenes; Transcription, Genetic; Xenograft Model Antitumor Assays	2008
The postchemotherapy PSA surge syndrome. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome	2008
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer letters, 2008, Jul-08, Volume: 265, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Calixarenes; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Ovarian Neoplasms; Peptides; Proteins; Sesquiterpenes; Xenograft Model Antitumor Assays	2008
Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells. Journal of cell science, 2008, Apr-15, Volume: 121, Issue:Pt 8 Topics: Antineoplastic Agents; Chromatography, Affinity; DNA Repair; HeLa Cells; Humans; Hydrolysis; Proteasome Endopeptidase Complex; RNA Polymerase II; Sesquiterpenes; Transcription, Genetic; Ubiquitin	2008
Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven. The Journal of organic chemistry, 2009, Dec-18, Volume: 74, Issue:24 Topics: Allyl Compounds; Antineoplastic Agents; Catalysis; Copper; Hydrogen; Magnetic Resonance Spectroscopy; Models, Chemical; Sesquiterpenes; Spiro Compounds; Stereoisomerism	2009
Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 343, Issue:2 Topics: 15-Oxoprostaglandin 13-Reductase; Animals; Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Antioxidants; Biotransformation; Blotting, Western; Cell Line, Tumor; Cell Survival; Cloning, Molecular; Enzyme Induction; Humans; Indicators and Reagents; Kinetics; NF-E2-Related Factor 2; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Rats; Recombinant Proteins; Sesquiterpenes; Up-Regulation	2012
Sulfotransferase-independent genotoxicity of illudin S and its acylfulvene derivatives in bacterial and mammalian cells. Archives of toxicology, 2014, Volume: 88, Issue:1 Topics: Animals; Arylsulfotransferase; Cell Line; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Humans; Mutagenicity Tests; Mutagens; Mutation; Polycyclic Sesquiterpenes; Salmonella typhimurium; Sesquiterpenes; Sister Chromatid Exchange; Spiro Compounds; Sulfotransferases	2014
ERCC6L2 mutations link a distinct bone-marrow-failure syndrome to DNA repair and mitochondrial function. American journal of human genetics, 2014, Feb-06, Volume: 94, Issue:2 Topics: Acetylcysteine; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Damage; DNA Helicases; DNA Repair; Female; Gene Knockdown Techniques; HEK293 Cells; HeLa Cells; Hemoglobinuria, Paroxysmal; Histones; Humans; Male; Mitochondria; Mitomycin; Mutation; Pedigree; Phosphorylation; Reactive Oxygen Species; Sesquiterpenes	2014
Hydroxyurea derivatives of irofulven with improved antitumor efficacy. Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7 Topics: Acetylation; Agaricales; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Humans; Hydroxyurea; Mice, Inbred BALB C; Neoplasms; Polycyclic Sesquiterpenes; Sesquiterpenes	2016
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 04-01, Volume: 27, Issue:7 Topics: Antineoplastic Agents; Cisplatin; DNA Repair; Humans; Sesquiterpenes; Urinary Bladder Neoplasms; Xeroderma Pigmentosum Group D Protein	2021
Morning for Irofulven, What Could be fiNER? Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 04-01, Volume: 27, Issue:7 Topics: Antineoplastic Agents, Alkylating; DNA Repair; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Sesquiterpenes	2021
Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. Scientific reports, 2023, Nov-23, Volume: 13, Issue:1 Topics: Carcinoma, Renal Cell; DNA Damage; DNA Repair; Humans; Kidney Neoplasms; Sesquiterpenes; Ultraviolet Rays; Xeroderma Pigmentosum Group D Protein	2023